Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
About this episode
Matt Winton, Ph.D. discusses late-stage development and commercial planning for neflamapimod in dementia with Lewy bodies.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the P...
More episodes of Business Of Biotech
- BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
- BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
- Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
- Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
- Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.